Table of Content

1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 14
1.2.6 Market Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17

2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 25
2.2 Major Growth Drivers 27
2.3 Market Restraints and Challenges 30
2.4 Emerging Opportunities and Market Trends 33
2.5 Porter’s Fiver Forces Analysis 37

3 Segmentation of Asia Pacific Market by Vaccine Type 41
3.1 Market Overview by Vaccine Type 41
3.2 Live/Attenuated Vaccines 43
3.3 Inactivated Vaccines 44
3.4 Subunit Vaccines 45
3.5 Toxoid Vaccines 46
3.6 Conjugate Vaccines 47
3.7 Recombinant Vector Vaccines 48
3.8 Other Vaccines 49

4 Segmentation of Asia Pacific Market by Disease 50
4.1 Market Overview by Disease 50
4.2 Vaccines for Pneumococcal Disease 52
4.3 Vaccines for Poliovirus 53
4.4 Vaccines for Hepatitis 54
4.5 Vaccines for Influenza 55
4.6 Vaccines for Measles, Mumps, and Rubella (MMR) 56
4.7 Vaccines for Varicella 57
4.8 Vaccines for Human Papilloma Virus 58
4.9 Vaccines for COVID-19 59
4.10 Vaccines for Other Diseases 60

5 Segmentation of Asia Pacific Market by Administration 61
5.1 Market Overview by Administration 61
5.2 Intramuscular Route 63
5.3 Subcutaneous Route 64
5.4 Oral Route 65
5.5 Intravenous Injection 66
5.6 Other Administration Routes 67

6 Segmentation of Asia Pacific Market by Patient 68
6.1 Market Overview by Patient 68
6.2 Pediatric Vaccines 70
6.3 Adult Vaccines 72

7 Asia-Pacific Market 2019-2026 by Country 74
7.1 Overview of Asia-Pacific Market 74
7.2 China 77
7.3 Japan 80
7.4 India 84
7.5 Australia 87
7.6 South Korea 90
7.7 Rest of APAC Region 93

8 Competitive Landscape 95
8.1 Overview of Key Vendors 95
8.2 New Product Launch, Partnership, Investment, and M&A 98
8.3 Company Profiles 99
AstraZeneca plc 99
Bavarian Nordic A/S 101
China National Biotec Group Company Ltd. 102
CSL Ltd. 103
Daiichi Sankyo Co. Ltd 104
Emergent BioSolutions Inc. 105
GlaxoSmithKline PLC 106
Johnson & Johnson 107
Merck & Co. 108
Novavax, Inc. 109
Pfizer Inc. 110
Sanofi SA 111
Takeda Pharmaceutical Co. Ltd 112

9 Investing in Asia Pacific Market: Risk Assessment and Management 113
9.1 Risk Evaluation of Asia Pacific Market 113
9.2 Critical Success Factors (CSFs) 116
Related Reports and Products 119
_



List of Figures


Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2026 17
Figure 5. Asia Pacific Preventive Vaccines Market, 2019-2026, $ mn 20
Figure 6. Development Stages of Preventive Vaccines 21
Figure 7. Impact of COVID-19 on Business 25
Figure 8. Primary Drivers and Impact Factors of Asia Pacific Preventive Vaccines Market 27
Figure 9. Primary Restraints and Impact Factors of Asia Pacific Preventive Vaccines Market 30
Figure 10. Investment Opportunity Analysis 34
Figure 11. Porter’s Fiver Forces Analysis of Asia Pacific Preventive Vaccines Market 37
Figure 12. Breakdown of Asia Pacific Preventive Vaccines Market by Vaccine Type, 2019-2026, % of Revenue 42
Figure 13. Contribution to Asia Pacific 2020-2026 Cumulative Revenue by Vaccine Type, Value ($ mn) and Share (%) 42
Figure 14. Asia Pacific Preventive Vaccines Market: Live/Attenuated Vaccines, 2016-2026, $ mn 43
Figure 15. Asia Pacific Preventive Vaccines Market: Inactivated Vaccines, 2016-2026, $ mn 44
Figure 16. Asia Pacific Preventive Vaccines Market: Subunit Vaccines, 2016-2026, $ mn 45
Figure 17. Asia Pacific Preventive Vaccines Market: Toxoid Vaccines, 2016-2026, $ mn 46
Figure 18. Asia Pacific Preventive Vaccines Market: Conjugate Vaccines, 2016-2026, $ mn 47
Figure 19. Asia Pacific Preventive Vaccines Market: Recombinant Vector Vaccines, 2016-2026, $ mn 48
Figure 20. Asia Pacific Preventive Vaccines Market: Other Vaccines, 2016-2026, $ mn 49
Figure 21. Breakdown of Asia Pacific Preventive Vaccines Market by Disease, 2019-2026, % of Revenue 51
Figure 22. Contribution to Asia Pacific 2020-2026 Cumulative Revenue by Disease, Value ($ mn) and Share (%) 51
Figure 23. Asia Pacific Preventive Vaccines Market: Vaccines for Pneumococcal Disease, 2016-2026, $ mn 52
Figure 24. Asia Pacific Preventive Vaccines Market: Vaccines for Poliovirus, 2016-2026, $ mn 53
Figure 25. Asia Pacific Preventive Vaccines Market: Vaccines for Hepatitis, 2016-2026, $ mn 54
Figure 26. Asia Pacific Preventive Vaccines Market: Vaccines for Influenza, 2016-2026, $ mn 55
Figure 27. Asia Pacific Preventive Vaccines Market: Vaccines for Measles, Mumps, and Rubella (MMR), 2016-2026, $ mn 56
Figure 28. Asia Pacific Preventive Vaccines Market: Vaccines for Varicella, 2016-2026, $ mn 57
Figure 29. Asia Pacific Preventive Vaccines Market: Vaccines for Human Papilloma Virus, 2016-2026, $ mn 58
Figure 30. Asia Pacific Preventive Vaccines Market: Vaccines for COVID-19, 2016-2026, $ mn 59
Figure 31. Asia Pacific Preventive Vaccines Market: Vaccines for Other Diseases, 2016-2026, $ mn 60
Figure 32. Breakdown of Asia Pacific Preventive Vaccines Market by Administration, 2019-2026, % of Revenue 62
Figure 33. Contribution to Asia Pacific 2020-2026 Cumulative Revenue by Administration, Value ($ mn) and Share (%) 62
Figure 34. Asia Pacific Preventive Vaccines Market: Intramuscular Route, 2016-2026, $ mn 63
Figure 35. Asia Pacific Preventive Vaccines Market: Subcutaneous Route, 2016-2026, $ mn 64
Figure 36. Asia Pacific Preventive Vaccines Market: Oral Route, 2016-2026, $ mn 65
Figure 37. Asia Pacific Preventive Vaccines Market: Intravenous Injection, 2016-2026, $ mn 66
Figure 38. Asia Pacific Preventive Vaccines Market: Other Administration Routes, 2016-2026, $ mn 67
Figure 39. Breakdown of Asia Pacific Preventive Vaccines Market by Patient, 2019-2026, % of Revenue 68
Figure 40. Contribution to Asia Pacific 2020-2026 Cumulative Revenue by Patient, Value ($ mn) and Share (%) 69
Figure 41. Asia Pacific Preventive Vaccines Market: Pediatric Vaccines, 2016-2026, $ mn 70
Figure 42. Asia Pacific Preventive Vaccines Market: Adult Vaccines, 2016-2026, $ mn 72
Figure 43. Breakdown of APAC Preventive Vaccines Market by Country, 2019 and 2026, % of Revenue 75
Figure 44. Contribution to APAC 2020-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%) 76
Figure 45. Preventive Vaccines Market in China, 2016-2026, $ mn 77
Figure 46. Preventive Vaccines Market in Japan, 2016-2026, $ mn 81
Figure 47. Preventive Vaccines Market in India, 2016-2026, $ mn 84
Figure 48. Preventive Vaccines Market in Australia, 2016-2026, $ mn 87
Figure 49. Preventive Vaccines Market in South Korea, 2016-2026, $ mn 90
Figure 50. Preventive Vaccines Market in Rest of APAC, 2016-2026, $ mn 93
Figure 51. Growth Stage of Asia Pacific Preventive Vaccines Industry over the Forecast Period 95


List of Tables


Table 1. Snapshot of Asia Pacific Preventive Vaccines Market in Balanced Perspective, 2019-2026 18
Table 2. Growth Rate of World Real GDP, 2017-2021 23
Table 3. Main Product Trends and Market Opportunities in Asia Pacific Preventive Vaccines Market 33
Table 4. Asia Pacific Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 41
Table 5. Asia Pacific Preventive Vaccines Market by Disease, 2016-2026, $ mn 50
Table 6. Asia Pacific Preventive Vaccines Market by Administration, 2016-2026, $ mn 61
Table 7. Asia Pacific Preventive Vaccines Market by Patient, 2016-2026, $ mn 68
Table 8. Asia Pacific Preventive Vaccines Market: Pediatric Vaccines by Disease, 2016-2026, $ mn 71
Table 9. Asia Pacific Preventive Vaccines Market: Adult Vaccines by Disease, 2016-2026, $ mn 73
Table 10. APAC Preventive Vaccines Market by Country, 2016-2026, $ mn 75
Table 11. China Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 78
Table 12. China Preventive Vaccines Market by Disease, 2016-2026, $ mn 78
Table 13. China Preventive Vaccines Market by Administration, 2016-2026, $ mn 79
Table 14. Japan Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 82
Table 15. Japan Preventive Vaccines Market by Disease, 2016-2026, $ mn 82
Table 16. Japan Preventive Vaccines Market by Administration, 2016-2026, $ mn 83
Table 17. India Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 85
Table 18. India Preventive Vaccines Market by Disease, 2016-2026, $ mn 85
Table 19. India Preventive Vaccines Market by C Administration, 2016-2026, $ mn 86
Table 20. Australia Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 88
Table 21. Australia Preventive Vaccines Market by Disease, 2016-2026, $ mn 88
Table 22. Australia Preventive Vaccines Market by Administration, 2016-2026, $ mn 89
Table 23. South Korea Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 91
Table 24. South Korea Preventive Vaccines Market by Disease, 2016-2026, $ mn 91
Table 25. South Korea Preventive Vaccines Market by Administration, 2016-2026, $ mn 92
Table 26. Preventive Vaccines Market in Rest of APAC by Country, 2016-2026, $ mn 94
Table 27. AstraZeneca plc: Company Snapshot 99
Table 28. AstraZeneca plc: Business Segmentation 99
Table 29. AstraZeneca plc: Product Portfolio 100
Table 30. AstraZeneca plc: Revenue, 2016-2018, $ mn 100
Table 31. AstraZeneca plc: Recent Developments 100
Table 32. Risk Evaluation for Investing in Asia Pacific Market, 2019-2026 114
Table 33. Critical Success Factors and Key Takeaways 117